#1 Clinical Trials Search in Europe

Dasatinib

Dasatinib is an oral tyrosine kinase inhibitor that has shown promise in treating various types of cancer. This article summarizes key findings from clinical trials investigating the use of dasatinib in conditions such as chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), prostate cancer, breast cancer, and other solid tumors. We’ll explore its efficacy, safety profile, and potential as a treatment option for patients with these challenging diseases.

Table of Contents

What is Dasatinib?

Dasatinib, also known by its brand name Sprycel[1], is a medication used to treat various types of blood cancers and other blood disorders. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking certain proteins that contribute to cancer cell growth[2].

What Conditions Does Dasatinib Treat?

Dasatinib is used to treat several conditions, including:

  • Chronic Myelogenous Leukemia (CML): A type of blood cancer where the bone marrow produces too many white blood cells[1].
  • Acute Lymphoblastic Leukemia (ALL): A fast-growing cancer of the white blood cells[3].
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow[4].
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[5].
  • Waldenström Macroglobulinemia: A rare type of blood cancer[6].

How Does Dasatinib Work?

Dasatinib is a targeted therapy that works by blocking specific proteins in cancer cells. It primarily targets a protein called BCR-ABL, which is responsible for the uncontrolled growth of cancer cells in some types of leukemia. By inhibiting this protein, Dasatinib can slow down or stop the growth of cancer cells[2].

In addition to BCR-ABL, Dasatinib also targets other proteins involved in cancer growth, such as Src kinases. This makes it effective against a wider range of blood cancers and disorders[7].

How is Dasatinib Administered?

Dasatinib is typically taken orally in tablet form. The dosage and frequency can vary depending on the specific condition being treated and the patient’s response to the medication. Some common administration methods include:

  • Once daily dosing, usually between 100-140 mg[8].
  • Twice daily dosing, often 70 mg in the morning and evening[7].

It’s important to take Dasatinib exactly as prescribed by your doctor. The medication can be taken with or without food, but it’s best to be consistent in how you take it[2].

Ongoing Clinical Trials

Researchers are continuously studying Dasatinib to understand its full potential and optimize its use. Some ongoing clinical trials are exploring:

  • Dasatinib in combination with other drugs for various blood cancers[3].
  • The effectiveness of Dasatinib in treating solid tumors[8].
  • Optimizing Dasatinib dosing based on individual patient characteristics[1].

Potential Side Effects

Like all medications, Dasatinib can cause side effects. Some common side effects include:

  • Fluid retention or swelling
  • Lowered blood cell counts
  • Headache
  • Fatigue
  • Nausea or diarrhea
  • Skin rash

More serious side effects, though less common, can include lung problems (pleural effusion) and heart rhythm changes. It’s crucial to report any side effects to your healthcare provider[1][8].

Monitoring During Treatment

While on Dasatinib, your doctor will closely monitor your progress and adjust your treatment as needed. This typically involves:

  • Regular blood tests to check blood cell counts and liver function[2].
  • Bone marrow biopsies to assess the response to treatment[7].
  • Monitoring for side effects and complications[1].

Your healthcare team may also perform tests to check the levels of Dasatinib in your blood, which can help optimize your dosage[1].

Cancer Type Key Findings Dosage Efficacy Measures Safety Profile
Chronic Myeloid Leukemia (CML) Effective in imatinib-resistant or intolerant patients; high rates of major cytogenetic response 50-140 mg daily Major cytogenetic response, complete hematologic response, progression-free survival Generally well-tolerated; common side effects include cytopenias and fluid retention
Acute Lymphoblastic Leukemia (ALL) Promising results in Ph+ ALL; improved hematologic responses 70-140 mg daily Major hematologic response, overall survival Similar to CML; requires careful monitoring for infections
Prostate Cancer Mixed results; some patients showed PSA response and disease stabilization 100-140 mg daily PSA response, progression-free survival, bone marker changes Generally tolerable; fatigue and gastrointestinal effects common
Triple-Negative Breast Cancer Limited efficacy as single agent; potential in combination therapy 70-100 mg twice daily Objective response rate, clinical benefit rate Manageable toxicity; pleural effusion and cytopenias observed
Other Solid Tumors Ongoing research; potential in specific molecular subtypes Varies by study Tumor response, biomarker changes Similar to other indications; individualized monitoring needed

FAQ

  • What is dasatinib and how does it work? Dasatinib is an oral tyrosine kinase inhibitor. It works by blocking certain proteins that are important for the survival of cancer cells, particularly those with the BCR-ABL gene mutation found in some leukemias. By interfering with these proteins, dasatinib can help control the growth and spread of cancer cells.
  • In which types of cancer has dasatinib been studied? Clinical trials have investigated dasatinib in various cancers, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), prostate cancer, triple-negative breast cancer, and other solid tumors. It has shown particular promise in treating CML and Philadelphia chromosome-positive leukemias.
  • What are the common side effects of dasatinib? Common side effects of dasatinib include low blood cell counts (anemia, neutropenia, thrombocytopenia), fatigue, headache, nausea, diarrhea, and skin rash. Some patients may also experience fluid retention or pleural effusion (fluid around the lungs). It's important to discuss potential side effects with your doctor.
  • How is dasatinib typically administered? Dasatinib is usually taken orally as tablets. The dosage and frequency can vary depending on the specific condition being treated and the individual patient. In clinical trials, doses ranged from 50 mg to 140 mg, taken once or twice daily. Your doctor will determine the appropriate dosage for your situation.
  • Has dasatinib been approved for use outside of clinical trials? Yes, dasatinib (brand name Sprycel) has been approved by regulatory agencies like the FDA for certain indications, particularly for treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, its use in other cancers may still be considered investigational and part of ongoing clinical research.

Ongoing Clinical Trials on Dasatinib

  • Study on the Safety and Effects of Dasatinib in Patients with Recent HIV-1 Infection

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of dasatinib treatment in children and adolescents with Philadelphia chromosome-positive leukemia who cannot take imatinib or for whom imatinib is not effective

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study on the Safety and Effects of Dasatinib for Reducing Inflammation in People with HIV on Antiretroviral Therapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Dasatinib and Quercetin for Patients with Osteoporosis or Osteopenia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Dasatinib and Quercetin combination for treating liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Tyrosine kinase inhibitor: A type of drug that blocks specific enzymes called tyrosine kinases, which are involved in cell signaling and growth. These inhibitors can help stop cancer cells from growing and dividing.
  • BCR-ABL: A fusion gene found in certain types of leukemia, particularly chronic myeloid leukemia (CML). It results from a genetic abnormality called the Philadelphia chromosome and produces an abnormal protein that promotes cancer cell growth.
  • Philadelphia chromosome: A genetic abnormality found in some leukemia patients, where parts of chromosomes 9 and 22 switch places. This creates the BCR-ABL fusion gene, which is targeted by drugs like dasatinib.
  • Chronic myeloid leukemia (CML): A type of blood cancer that begins in the bone marrow and affects the development of white blood cells. It is often associated with the presence of the Philadelphia chromosome.
  • Acute lymphoblastic leukemia (ALL): A fast-growing cancer of the blood and bone marrow that affects lymphoid cells. Some cases are Philadelphia chromosome-positive (Ph+ ALL) and may be treated with drugs like dasatinib.
  • Triple-negative breast cancer: A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. It is typically more aggressive and has fewer treatment options than other types of breast cancer.
  • Cytogenetic response: A measure of treatment effectiveness in leukemia, based on the percentage of cells with the Philadelphia chromosome. A complete cytogenetic response means no detectable Ph+ cells in the bone marrow.
  • Hematologic response: A measure of treatment effectiveness in blood cancers, based on the normalization of blood cell counts and the absence of immature cells (blasts) in the blood and bone marrow.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.

References

  1. https://clinicaltrials.gov/study/NCT01916785
  2. https://clinicaltrials.gov/study/NCT00364286
  3. https://clinicaltrials.gov/study/NCT00940524
  4. https://clinicaltrials.gov/study/NCT06055621
  5. https://clinicaltrials.gov/study/NCT00624585
  6. https://clinicaltrials.gov/study/NCT04115059
  7. https://clinicaltrials.gov/study/NCT00255346
  8. https://clinicaltrials.gov/study/NCT00339144